Please login or register to print this page.

The British Journal
of Cardiology

This website is intended for healthcare professionals only

2010, Volume 17, Supplement 1

NEWS
Br J Cardiol 2009;17(Suppl 1):S1-S3

Aspirin – reassessing its role in cardiovascular disease

Report from a scientific roundtable meeting held at the Royal Society of Medicine, London, in October...

Read More

NEWS
Br J Cardiol 2009;17(Suppl 1):S8-S9

Aspirin – scope and limitations

Identifying targets in the thrombosis pathway Figure 1 summarises the central role of platelets in the genesis of thrombosis.1 The platelet is initially activated in...

Read More

NEWS
Br J Cardiol 2009;17(Suppl 1):S3-S4

How do antithrombotics work?

Antithrombotic drugs act principally by inhibiting platelet function directly (for example, aspirin, clopidogrel and dipyridamole) or, via thrombin inhibition, by inhibiting platelet activation and fibrin...

Read More

NEWS
Br J Cardiol 2010;17(Suppl 1):S1-S12

Discussion

The efficacy of aspirin in secondary prevention of cardiovascular disease is well understood but its position in primary prevention of cardiovascular events is less...

Read More

NEWS
Br J Cardiol 2009;17(Suppl 1):S5-S7

What is aspirin resistance?

Variable and sometimes ineffective drug treatment is not uncommon in the treatment of cardiovascular disease.(1) In most cases lack of patient compliance is the explanation...

Read More

NEWS
Br J Cardiol 2009;17(Suppl 1):S10-11

Is dual antiplatelet therapy needed for all CVD patients?

Aspirin has revolutionised the management of cardiovascular disease (CVD) but it is apparent that clinical outcomes need to be improved further. The three-year follow-up of...

Read More

Close

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

Find out more about our membership benefits

Close

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.

Find out more about our membership benefits